<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TIMOLOL MALEATE- timolol maleate tablet </strong><br>Mylan Pharmaceuticals Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_0b85f2c2-d53a-405c-b16d-9a09073c9640"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Timolol maleate is a nonselective beta-adrenergic receptor blocking agent. The chemical name for timolol maleate is (<span class="Italics">S</span>)-1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-2-propanol (<span class="Italics">Z</span>)-2-butenedioate (1:1) salt. It possesses an asymmetric carbon atom in its structure and is provided as the levo isomer. Its molecular formula is C<span class="Sub">13</span>H<span class="Sub">24</span>N<span class="Sub">4</span>O<span class="Sub">3</span>S•C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span> and its structural formula is:</p>
<div class="Figure">
<a name="id90470773"></a><img alt="Timolol Maleate Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57c62928-63d8-4505-9b9e-c085a3a12c95&amp;name=7f38508a-5a77-4fe1-b1bc-fb26470b02bb-01.jpg">
</div>
<p>Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol.</p>
<p>Timolol maleate is supplied as tablets containing 5 mg, 10 mg and 20 mg timolol maleate for oral administration. Inactive ingredients are: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate, FD&amp;C Blue #2 aluminum lake, and D&amp;C Yellow #10 aluminum lake.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_cp"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Timolol maleate is a beta<span class="Sub">1</span> and beta<span class="Sub">2</span> (nonselective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic activity.</p>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_pharmacodynamics"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">Clinical pharmacology studies have confirmed the beta-adrenergic blocking activity as shown by (1) changes in resting heart rate and response of heart rate to changes in posture; (2) inhibition of isoproterenol-induced <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; (3) alteration of the response to the Valsalva maneuver and amyl nitrite administration; and (4) reduction of heart rate and blood pressure changes on exercise.</p>
<p>Timolol decreases the positive chronotropic, positive inotropic, bronchodilator, and vasodilator responses caused by beta-adrenergic receptor agonists. The magnitude of this decreased response is proportional to the existing sympathetic tone and the concentration of timolol at receptor sites.</p>
<p>In normal volunteers, the reduction in heart rate response to a standard exercise was dose dependent over the test range of 0.5 to 20 mg, with a peak reduction at 2 hours of approximately 30% at higher doses.</p>
<p>Beta-adrenergic receptor blockade reduces <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.</p>
<p>Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity. Such an effect in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or other bronchospastic conditions is potentially dangerous.</p>
<p>Clinical studies indicate that timolol maleate at a dosage of 20 to 60 mg/day reduces blood pressure without causing <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> in most patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span>. Administration of timolol to patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> results initially in a decrease in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, little immediate change in blood pressure, and an increase in calculated peripheral resistance. With continued administration of timolol, blood pressure decreases within a few days, <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> usually remains reduced, and peripheral resistance <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> toward pretreatment levels. Plasma volume may decrease or remain unchanged during therapy with timolol. In the majority of patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> timolol also decreases plasma renin activity. Dosage adjustment to achieve optimal antihypertensive effect may require a few weeks. When therapy with timolol is discontinued, the blood pressure tends to return to pretreatment levels gradually. In most patients the antihypertensive activity of timolol is maintained with long-term therapy and is well tolerated.</p>
<p>The mechanism of the antihypertensive effects of beta-adrenergic receptor blocking agents is not established at this time. Possible mechanisms of action include reduction in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, reduction in plasma renin activity, and a central nervous system sympatholytic action.</p>
<p>A Norwegian multi-center, double-blind study, which included patients 20 to 75 years of age, compared the effects of timolol maleate with placebo in 1,884 patients who had survived the acute phase of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>. Patients with systolic blood pressure below 100 mm Hg, <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">sick sinus syndrome</span> and contraindications to beta-blockers, including uncontrolled <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, second- or third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (&lt; 50 beats per minute), were excluded from the multi-center trial. Therapy with timolol, begun 7 to 28 days following <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, was shown to reduce overall mortality; this was primarily attributable to a reduction in cardiovascular mortality. Timolol significantly reduced the incidence of <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden deaths</span> (<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> occurring without symptoms or within 24 hours of the onset of symptoms), including those occurring within one hour, and particularly instantaneous <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> (those occurring without preceding symptoms). The protective effect of timolol was consistent regardless of age, sex or site of <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>. The effect was clearest in patients with a first <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> who were considered at a high risk of dying, defined as those with one or more of the following characteristics during the acute phase: transient <span class="product-label-link" type="condition" conceptid="439846" conceptname="Left heart failure">left ventricular failure</span>, <span class="product-label-link" type="condition" conceptid="314658" conceptname="Cardiomegaly">cardiomegaly</span>, newly appearing <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> or flutter, systolic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, or <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (ASAT) levels greater than four times the upper limit of normal. Therapy with timolol also reduced the incidence of nonfatal reinfarction. The mechanism of the protective effect of timolol is unknown.</p>
<p>Timolol was studied for the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> in placebo-controlled clinical trials involving 400 patients, mostly women between the ages of 18 and 66 years. Common <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> was the most frequent diagnosis. All patients had at least two <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> per month at baseline. Approximately 50 percent of patients who received timolol had a reduction in the frequency of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> of at least 50 percent, compared to a similar decrease in frequency in 30 percent of patients receiving placebo. The most common cardiovascular adverse effect was <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (5%).</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_fecd8f78-9689-4f3a-ac80-a3a0424e4f2f"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics and Metabolism</h2>
<p class="First">Timolol maleate is rapidly and nearly completely absorbed (about 90%) following oral ingestion. Detectable plasma levels of timolol occur within one-half hour and peak plasma levels occur in about one to two hours. The drug half-life in plasma is approximately 4 hours and this is essentially unchanged in patients with moderate <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. Timolol is partially metabolized by the liver and timolol and its metabolites are excreted by the kidney. Timolol is not extensively bound to plasma proteins; i.e., &lt; 10% by equilibrium dialysis and approximately 60% by ultrafiltration. An <span class="Italics">in vitro</span> hemodialysis study, using <span class="Sup">14</span>C timolol added to human plasma or whole blood, showed that timolol was readily dialyzed from these fluids; however, a study of patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> showed that timolol did not dialyze readily. Plasma levels following oral administration are about half those following intravenous administration indicating approximately 50% first pass metabolism. The level of beta sympathetic activity varies widely among individuals, and no simple correlation exists between the dose or plasma level of timolol maleate and its therapeutic activity. Therefore, objective clinical measurements such as reduction of heart rate and/or blood pressure should be used as guides in determining the optimal dosage for each patient.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_23462f5e-2538-46cf-a4ed-53367d598ac4"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0c2bed5f-d82f-4c85-83b7-e296e0ceed35"></a><a name="section-3.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">Timolol maleate tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_368d6734-adf6-4845-80fe-33d3b53efbd9"></a><a name="section-3.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">Timolol is indicated in patients who have survived the acute phase of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_df8a0ce5-0319-44e8-aa74-78b91824dbfc"></a><a name="section-3.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></h2>
<p class="First">Timolol is indicated for the prophylaxis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_contraindications"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Timolol maleate is contraindicated in patients with bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or with a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, or severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (see <a href="#i4i_warnings_id_warnings">WARNINGS</a>); <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>; second- and third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>; overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> (see <a href="#i4i_warnings_id_warnings">WARNINGS</a>); <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to this product.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_93fca444-e2d0-4332-9813-d933264659a5"></a><a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure. Although beta-blockers should be avoided in overt <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, they can be used, if necessary, with caution in patients with a history of failure who are well compensated, usually with digitalis and diuretics. Both digitalis and timolol maleate slow AV conduction. If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> persists, therapy with timolol maleate should be withdrawn.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1051b042-b619-40ce-85dc-3cff7ff4a28e"></a><a name="section-5.2"></a><p></p>
<h2>In Patients Without a History of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">Continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. At the first sign or symptom of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, patients receiving timolol should be digitalized and/or be given a diuretic, and the response observed closely. If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> continues, despite adequate digitalization and diuretic therapy, timolol should be withdrawn.</p>
<div class="Warning">
<a name="id_bfe99334-69e8-4fe2-b107-2c249e340d83"></a><a name="section-5.2.1"></a><p></p>
<h3>Exacerbation of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Ischemic Heart Disease</span> Following Abrupt Withdrawal</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have occurred after <span class="Italics">abrupt</span> discontinuation of such therapy. When discontinuing chronically administered timolol maleate, particularly in patients with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, the dosage should be gradually reduced over a period of one to two weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, timolol maleate administration should be reinstituted promptly, at least temporarily, and other measures appropriate for the management of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician's advice. Because <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> is common and may be unrecognized, it may be prudent not to discontinue timolol maleate therapy abruptly even in patients treated only for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c381adc7-3cb2-4c04-a58e-58de96dd3923"></a><a name="section-5.3"></a><p></p>
<h2>Obstructive Pulmonary Disease</h2>
<p class="First">PATIENTS WITH <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">CHRONIC OBSTRUCTIVE PULMONARY DISEASE</span> (e.g., <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">CHRONIC BRONCHITIS</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">EMPHYSEMA</span>) OF MILD OR MODERATE SEVERITY, BRONCHOSPASTIC DISEASE OR A HISTORY OF BRONCHOSPASTIC DISEASE (OTHER THAN BRONCHIAL <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">ASTHMA</span> OR A HISTORY OF BRONCHIAL <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">ASTHMA</span>, IN WHICH ‘TIMOLOL MALEATE’ IS CONTRAINDICATED, see <a href="#i4i_contraindications_id_contraindications">CONTRAINDICATIONS</a>), SHOULD IN GENERAL NOT RECEIVE BETA-BLOCKERS, INCLUDING ‘TIMOLOL’. However, if timolol is necessary in such patients, then the drug should be administered with caution since it may block bronchodilation produced by endogenous and exogenous catecholamine stimulation of beta<span class="Sub">2</span> receptors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1bf5267d-fd1f-4447-8259-3b374f470528"></a><a name="section-5.4"></a><p></p>
<h2>Major Surgery</h2>
<p class="First">The necessity or desirability of withdrawal of beta-blocking therapy prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor blocking agents have been subject to protracted severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of beta-adrenergic receptor blocking agents.</p>
<p>If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of such agonists as isoproterenol, dopamine, dobutamine or norepinephrine (see <a href="#i4i_overdosage_id_overdosage">OVERDOSAGE</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5a2f9eb4-5cca-40d4-802a-721f79cd204b"></a><a name="section-5.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</h2>
<p class="First">Timolol should be administered with caution in patients subject to spontaneous <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or to diabetic patients (especially those with labile <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4656b90c-9a02-4aae-91f8-de556aa9e1d1"></a><a name="section-5.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></h2>
<p class="First">Beta-adrenergic blockade may mask certain clinical signs (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. Patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> should be managed carefully to avoid abrupt withdrawal of beta-blockade which might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_98ef18c0-f7d4-46d6-ba36-6606b63c46a4"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_c93e0aa3-4a67-4d47-b046-eddc56bb49bd"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_hepatic"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold">Impaired Hepatic or Renal Function</span></h3>
<p class="First">Since timolol is partially metabolized in the liver and excreted mainly by the kidneys, dosage reductions may be necessary when hepatic and/or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> is present.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dosing"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold">Dosing in the Presence of Marked <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></span></h3>
<p class="First">Although the pharmacokinetics of timolol are not greatly altered by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, marked hypotensive responses have been seen in patients with marked <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> undergoing dialysis after 20 mg doses. Dosing in such patients should therefore be especially cautious.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b92030dd-2e4d-42e3-9b4c-aff99773e9d9"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span></span></h3>
<p class="First">Beta-adrenergic blockade has been reported to potentiate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> consistent with certain myasthenic symptoms (e.g., <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, and generalized <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>). Timolol has been reported rarely to increase <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in some patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> or myasthenic symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7e5e8635-8209-4334-940e-ed7083851723"></a><a name="section-6.1.4"></a><p></p>
<h3><span class="Bold">Cerebrovascular Insufficiency</span></h3>
<p class="First">Because of potential effects of beta-adrenergic blocking agents relative to blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_734a47d0-22b3-4205-a76e-69d7e602abab"></a><a name="section-6.2"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9a269b87-b9f1-4ade-9f62-fffcd7165bec"></a><a name="section-6.2.1"></a><p></p>
<h3><span class="Bold">Catecholamine-Depleting Drugs</span></h3>
<p class="First">Close observation of the patient is recommended when timolol is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, which may produce <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_67a6e303-9200-44ad-91f4-37322e4263e9"></a><a name="section-6.2.2"></a><p></p>
<h3><span class="Bold">Non-Steroidal Anti-Inflammatory Drugs</span></h3>
<p class="First">Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal anti-inflammatory drugs has been reported. When using these agents concomitantly, patients should be observed carefully to confirm that the desired therapeutic effect has been obtained.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_99b53ba7-3312-464c-85cb-9c940444fe4f"></a><a name="section-6.2.3"></a><p></p>
<h3><span class="Bold">Calcium Antagonists</span></h3>
<p class="First">Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, AV conduction disturbances, and <span class="product-label-link" type="condition" conceptid="439846" conceptname="Left heart failure">left ventricular failure</span> have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., nifedipine, while <span class="product-label-link" type="condition" conceptid="439846" conceptname="Left heart failure">left ventricular failure</span> and AV conduction disturbances were more likely to occur with either verapamil or diltiazem.</p>
<p>Intravenous calcium antagonists should be used with caution in patients receiving beta-adrenergic blocking agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_80eaaa1d-4bf2-4d1c-8881-2f5e0ca1fbc8"></a><a name="section-6.2.4"></a><p></p>
<h3><span class="Bold">Digitalis and Either Diltiazem or Verapamil</span></h3>
<p class="First">The concomitant use of beta-adrenergic blocking agents with digitalis and either diltiazem or verapamil may have additive effects in prolonging AV conduction time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e6d832bd-d03e-4fb9-9853-2efc5fa662d9"></a><a name="section-6.2.5"></a><p></p>
<h3><span class="Bold">Quinidine</span></h3>
<p class="First">Potentiated systemic beta-blockade (e.g., decreased heart rate) has been reported during combined treatment with quinidine and timolol, possibly because quinidine inhibits the metabolism of timolol via the P-450 enzyme, CYP2D6.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bda506b9-cd36-495d-b3a5-b4216bf22e5a"></a><a name="section-6.2.6"></a><p></p>
<h3><span class="Bold">Clonidine</span></h3>
<p class="First">Beta-adrenergic blocking agents may exacerbate the <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta-adrenergic blocking agent should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta-blocker therapy, the introduction of beta-adrenergic blocking agents should be delayed for several days after clonidine administration has stopped.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ed84f83e-a762-4536-9479-0a17e0074ecf"></a><a name="section-6.3"></a><p></p>
<h2>Risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reaction</span></h2>
<p class="First">While taking beta-blockers, patients with a history of <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopy</span> or a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_5a3af724-aa94-4332-bede-ed730822081c"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 2 year study of timolol maleate in rats, there was a statistically significant increase in the incidence of adrenal <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> in male rats administered 300 mg/kg/day (250 times<a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a> the maximum recommended human dose). Similar differences were not observed in rats administered doses equivalent to approximately 20 or 80 times<span class="Sup">1</span> the maximum recommended human dose.</p>
<p>In a lifetime study in mice, there were statistically significant increases in the incidence of benign and malignant pulmonary tumors, benign uterine <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> and mammary adenocarcinoma in female mice at 500 mg/kg/day (approximately 400 times<span class="Sup">1</span> the maximum recommended human dose), but not at a 5 or 50 mg/kg/day. In a subsequent study in female mice, in which postmortem examinations were limited to uterus and lungs, a statistically significant increase in the incidence of pulmonary tumors was again observed at 500 mg/kg/day.</p>
<p>The increased occurrence of mammary adenocarcinoma was associated with elevations in serum prolactin that occurred in female mice administered timolol maleate at 500 mg/kg/day, but not at doses of 5 or 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in rodents has been associated with administration of several other therapeutic agents which elevate serum prolactin, but no correlation between serum prolactin levels and mammary tumors has been established in man. Furthermore, in adult human female subjects who received oral dosages of up to 60 mg of timolol maleate, the maximum recommended daily human oral dosage, there were no clinically meaningful changes in serum prolactin.</p>
<p>Timolol maleate was devoid of mutagenic potential when elevated <span class="Italics">in vivo</span> (mouse) in the micronucleus test and cytogenetic assay (doses up to 800 mg/kg) and <span class="Italics">in vitro</span> in a neoplastic cell transformation assay (up to 100 mcg/mL). In Ames tests the highest concentrations of timolol employed, 5,000 or 10,000 mcg/plate, were associated with statistically significant elevations of revertants observed with tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA100 (in seven replicate assays), but not in three additional <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>. In the assays with tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA100, no consistent dose-response relationship was observed, nor did the ratio of test to control revertants reach 2. A ratio of 2 is usually considered the criterion for a positive Ames test.</p>
<p>Reproduction and fertility studies in rats showed no adverse effect on male or female fertility at doses up to 125 times<span class="Sup">1</span> the maximum recommended human dose.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd> Based on patient weight of 50 kg.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_9279b251-1aa6-460f-a4c3-81fdb2520156"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_4ec9e6c5-dbaf-490e-be33-bcb018e19d4a"></a><a name="section-6.5.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_42e67c6c-fee0-4240-b09a-73f41c5bc561"></a><a name="section-6.5.1.1"></a><p></p>
<h4><span class="Bold">Pregnancy Category C</span></h4>
<p class="First"><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies with timolol in mice, rats and rabbits at doses up to 50 mg/kg/day (approximately 40 times<span class="Sup">1</span> the maximum recommended daily human dose) showed no evidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1000 mg/kg/day (approximately 830 times<span class="Sup">1</span> the maximum recommended daily human dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of approximately 40 times<span class="Sup">1</span> the maximum recommended daily human dose, in this case without apparent maternotoxicity. There are no adequate and well controlled studies in pregnant women. Timolol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_263ea1dc-78d1-4ec7-ac81-d08eeb5411ed"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Timolol maleate has been detected in human milk. </p>
<p>Because of the potential for serious adverse reactions from timolol in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_6c886339-ae78-44cf-97c3-d9ab24b36803"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_d2363f99-295d-4829-94ed-6498a561274a"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of timolol for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</p>
<p>In a clinical study of timolol in patients who had survived the acute phase of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, approximately 350 patients (37%) were 65 to 75 years of age. Safety and efficacy were not different between these patients and younger patients (see <a href="#i4i_pharmacodynamics_id_pharmacodynamics">CLINICAL PHARMACOLOGY: Pharmacodynamics</a>).</p>
<p>Other reported clinical experience has not identified differences in response between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See <a href="#i4i_section_id_hepatic">PRECAUTIONS: Impaired Hepatic or Renal Function</a> and <a href="#i4i_section_id_dosing">Dosing in the Presence of Marked <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></a>.)</p>
<p>The results from 5 single- and/or multiple-dose PK studies comparing the impact of age on the PK of hydrochlorothiazide, when given in combination with other antihypertensive drugs, were consistent. They indicated a mean median increase in C<span class="Sub">max</span> and AUC of 38% and 99% respectively, in elderly relative to younger subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_a34312ec-cda4-457f-a2bc-c136b8c3688a"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Timolol maleate tablets are usually well tolerated in properly selected patients. Most adverse effects have been mild and transient. </p>
<p>In a multi-center (12 week) clinical trial comparing timolol maleate and placebo in hypertensive patients, the following adverse reactions were reported spontaneously and considered to be causally related to timolol maleate: </p>
<table width="100%">
<col width="24%">
<col width="18%">
<col width="10%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold"> </span></th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Timolol Maleate</span><br><span class="Bold">(n=176)</span><br><span class="Bold"><span class="Underline">%</span></span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(n=168)</span><br><span class="Bold"><span class="Underline">%</span></span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">BODY AS A WHOLE</p></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></p></td>
<td align="center"><p class="First">3.4</p></td>
<td align="center"><p class="First">0.6</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p></td>
<td align="center"><p class="First">1.7</p></td>
<td align="center"><p class="First">1.8</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></p></td>
<td align="center"><p class="First">0.6</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></p></td>
<td align="center"><p class="First">0.6</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">CARDIOVASCULAR</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span></p></td>
<td align="center"><p class="First">9.1</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span></p></td>
<td align="center"><p class="First">1.1</p></td>
<td align="center"><p class="First">0.6</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span></p></td>
<td align="center"><p class="First">0.6</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></p></td>
<td align="center"><p class="First">0.6</p></td>
<td align="center"><p class="First">1.2</p></td>
</tr>
<tr>
<td><p class="First">DIGESTIVE</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span></p></td>
<td align="center"><p class="First">0.6</p></td>
<td align="center"><p class="First">0.6</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></p></td>
<td align="center"><p class="First">0.6</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">SKIN</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p></td>
<td align="center"><p class="First">1.1</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">NERVOUS SYSTEM</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></p></td>
<td align="center"><p class="First">2.3</p></td>
<td align="center"><p class="First">1.2</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p></td>
<td align="center"><p class="First">0.6</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span></p></td>
<td align="center"><p class="First">0.6</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">PSYCHIATRIC</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  decreased libido</p></td>
<td align="center"><p class="First">0.6</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">RESPIRATORY</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p></td>
<td align="center"><p class="First">1.7</p></td>
<td align="center"><p class="First">0.6</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchial spasm</span></p></td>
<td align="center"><p class="First">0.6</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">rales</span></p></td>
<td align="center"><p class="First">0.6</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">SPECIAL SENSES</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span></p></td>
<td align="center"><p class="First">1.1</p></td>
<td align="center"><p class="First">0.6</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></p></td>
<td class="Botrule" align="center"><p class="First">0.6</p></td>
<td class="Botrule" align="center"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p>These data are representative of the incidence of adverse effects that may be observed in properly selected patients treated with timolol maleate, i.e., excluding patients with bronchospastic disease, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> or other contraindications to beta-blocker therapy.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> the incidence of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> was 5 percent.</p>
<p>In a <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> population studied in the Norwegian multi-center trial (see <a href="#i4i_clinical_pharmacology_id_cp">CLINICAL PHARMACOLOGY</a>), the frequency of the principal adverse reactions and the frequency with which these resulted in discontinuation of therapy in the timolol and placebo groups were:</p>
<table width="100%">
<col width="31%">
<col width="10%">
<col width="10%">
<col width="10%">
<col width="10%">
<thead>
<tr class="First">
<th class="Toprule" align="left" valign="top"><span class="Bold"> </span></th>
<th class="Toprule" align="left" colspan="2" valign="top">
<span class="Bold">Adverse Reaction</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</th>
<th class="Toprule" align="left" colspan="2" valign="top">
<span class="Bold">Withdrawal</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a>
</th>
</tr>
<tr class="Last">
<th class="Botrule" align="left" valign="top"><span class="Bold"> </span></th>
<th class="Botrule" align="left" valign="top">
<span class="Bold">Timolol</span><br><span class="Bold">(n=945)</span><br><span class="Bold"><span class="Underline">%</span></span>
</th>
<th class="Botrule" align="left" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(n=939)</span><br><span class="Bold"><span class="Underline">%</span></span>
</th>
<th class="Botrule" align="left" valign="top">
<span class="Bold">Timolol</span><br><span class="Bold">(n=945)</span><br><span class="Bold"><span class="Underline">%</span></span>
</th>
<th class="Botrule" align="left" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(n=939)</span><br><span class="Bold"><span class="Underline">%</span></span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>When an adverse reaction recurred in a patient, it is listed only once.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>Only principal reason for withdrawal in each patient is listed. These adverse reactions can also occur in patients treated for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Toprule" align="center"><p class="First">5</p></td>
<td class="Toprule" align="center"><p class="First">1</p></td>
<td class="Toprule" align="center"><p class="First">&lt;1</p></td>
<td class="Toprule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td><p class="First">Heart Rate &lt; 40 beats/minute</p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">&lt;1</p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>-Nonfatal</p></td>
<td align="center"><p class="First">8</p></td>
<td align="center"><p class="First">7</p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary Edema</span>-Nonfatal</p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">&lt;1</p></td>
<td align="center"><p class="First">&lt;1</p></td>
<td align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">Claudication</span></p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">1</p></td>
<td align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV Block</span> 2nd or 3rd Degree</p></td>
<td align="center"><p class="First">&lt;1</p></td>
<td align="center"><p class="First">&lt;1</p></td>
<td align="center"><p class="First">&lt;1</p></td>
<td align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4277903" conceptname="Sinoatrial block">Sinoatrial Block</span></p></td>
<td align="center"><p class="First">&lt;1</p></td>
<td align="center"><p class="First">&lt;1</p></td>
<td align="center"><p class="First">&lt;1</p></td>
<td align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">Cold Hands</span> and Feet</p></td>
<td align="center"><p class="First">8</p></td>
<td align="center"><p class="First">&lt;1</p></td>
<td align="center"><p class="First">&lt;1</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> or Digestive Disorders</p></td>
<td align="center"><p class="First">8</p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">1</p></td>
<td align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">1</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4279071" conceptname="Obstruction of bronchus">Bronchial Obstruction</span></p></td>
<td class="Botrule" align="center"><p class="First">2</p></td>
<td class="Botrule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule" align="center"><p class="First">1</p></td>
<td class="Botrule" align="center"><p class="First">&lt;1</p></td>
</tr>
</tbody>
</table>
<p>The following additional adverse effects have been reported in clinical experience with the drug: <span class="Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, extremity <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, decreased exercise tolerance, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; <span class="Italics">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, cerebral vascular <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, worsening of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, worsening of <span class="product-label-link" type="condition" conceptid="4109870" conceptname="Arterial insufficiency">arterial insufficiency</span>, Raynaud's phenomenon, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>; <span class="Italics">Digestive: </span><span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">gastrointestinal pain</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>; <span class="Italics">Hematologic: </span>nonthrombocytopenic <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>;<span class="Italics"> Endocrine: </span><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>; <span class="Italics">Skin: </span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>, increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>; <span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>; <span class="Italics">Nervous System: </span>local <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, increase in signs and symptoms of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>; <span class="Italics">Psychiatric: </span><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, diminished concentration, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>; <span class="Italics">Respiratory: </span><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>; <span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>; <span class="Italics">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, urination difficulties.</p>
<p>There have been reports of <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">retroperitoneal fibrosis</span> in patients receiving timolol maleate and in patients receiving other beta-adrenergic blocking agents. A causal relationship between this condition and therapy with beta-adrenergic blocking agents has not been established.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d4e34859-6e21-4595-863d-2d5536cb1327"></a><a name="section-7.1"></a><p></p>
<h2>Potential Adverse Effects</h2>
<p class="First">In addition, a variety of adverse effects not observed in clinical trials with timolol maleate, but reported with other beta-adrenergic blocking agents, should be considered potential adverse effects of timolol. <span class="Italics">Nervous System: </span>Reversible mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> progressing to <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span>; an acute reversible syndrome characterized by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> for time and place, short-term <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, slightly clouded sensorium, and decreased performance on neuropsychometrics; <span class="Italics">Cardiovascular: </span>Intensification of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> (see <a href="#i4i_contraindications_id_contraindications">CONTRAINDICATIONS</a>);<span class="Italics"> Digestive: </span>Mesenteric <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>; <span class="Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>; <span class="Italics">Allergic: </span>Erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> combined with aching and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> with <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>; <span class="Italics">Miscellaneous: </span>Peyronie's disease.</p>
<p>There have been reports of a syndrome comprising psoriasiform <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> sicca, <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span>, and sclerosing <span class="product-label-link" type="condition" conceptid="4157025" conceptname="Serositis">serositis</span> attributed to the beta-adrenergic receptor blocking agent, practolol. This syndrome has not been reported with timolol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_72f0620c-9e48-404c-9dd5-fa4c52e48d25"></a><a name="section-7.2"></a><p></p>
<h2>Clinical Laboratory Test Findings</h2>
<p class="First">Clinically important changes in standard laboratory parameters were rarely associated with the administration of timolol. Slight increases in blood urea nitrogen, serum potassium, uric acid, and triglycerides, and slight decreases in hemoglobin, hematocrit and HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> occurred, but were not progressive or associated with clinical manifestations. Increases in liver function tests have been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_overdosage"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Overdosage has been reported with timolol maleate tablets. A 30 year old female ingested 650 mg of timolol maleate (maximum recommended daily dose - 60 mg) and experienced second- and third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>. She recovered without treatment but approximately 2 months later developed irregular heart beat, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, faintness, increased pulse rate and borderline first degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>.</p>
<p>The oral LD<span class="Sub">50 </span>of the drug is 1190 and 900 mg/kg in female mice and female rats, respectively.</p>
<p>An <span class="Italics">in vitro</span> hemodialysis study, using <span class="Sup">14</span>C timolol added to human plasma or whole blood, showed that timolol was readily dialyzed from these fluids; however, a study of patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> showed that timolol did not dialyze readily.</p>
<p>The most common signs and symptoms to be expected with overdosage with a beta-adrenergic receptor blocking agent are symptomatic <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and acute <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. Therapy with timolol should be discontinued and the patient observed closely. The following additional therapeutic measures should be considered:</p>
<dl>
<dt>•</dt>
<dd> (1) <span class="Italics">Gastric lavage.</span>
</dd>
<dt>•</dt>
<dd> (2) <span class="Italics">Symptomatic <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>: </span>Use atropine sulfate intravenously in a dosage of 0.25 mg to 2 mg to induce vagal blockade. If <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> persists, intravenous isoproterenol hydrochloride should be administered cautiously. In refractory cases the use of a transvenous cardiac pacemaker may be considered.</dd>
<dt>•</dt>
<dd> (3) <span class="Italics"> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>: </span>Use sympathomimetic pressor drug therapy, such as dopamine, dobutamine or norepinephrine. In refractory cases the use of glucagon hydrochloride has been reported to be useful.</dd>
<dt>•</dt>
<dd> (4) <span class="Italics"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>: </span>Use isoproterenol hydrochloride. Additional therapy with aminophylline may be considered.</dd>
<dt>•</dt>
<dd> (5) <span class="Italics">Acute <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>:</span> Conventional therapy with digitalis, diuretics, and oxygen should be instituted immediately. In refractory cases the use of intravenous aminophylline is suggested. This may be followed if necessary by glucagon hydrochloride which has been reported to be useful.</dd>
<dt>•</dt>
<dd> (6) <span class="Italics"><span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">Heart block</span> (second- or third-degree): </span>Use isoproterenol hydrochloride or a transvenous cardiac pacemaker.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_18a1a887-9546-4ee0-adb1-cab7924372fb"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_75aaae9e-5573-410a-97b8-35f755568386"></a><a name="section-9.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">The usual initial dosage of timolol maleate is 10 mg twice a day, whether used alone or added to diuretic therapy. Dosage may be increased or decreased depending on heart rate and blood pressure response. The usual total maintenance dosage is 20 to 40 mg per day. Increases in dosage to a maximum of 60 mg per day divided into two doses may be necessary. There should be an interval of at least 7 days between increases in dosages. </p>
<p>Timolol maleate tablets may be used with a thiazide diuretic or with other antihypertensive agents. Patients should be observed carefully during initiation of such concomitant therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dfe3b5c8-5ad8-49b4-8217-080882245ebe"></a><a name="section-9.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">The recommended dosage for long-term <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use in patients who have survived the acute phase of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> is 10 mg given twice daily (see <a href="#i4i_clinical_pharmacology_id_cp">CLINICAL PHARMACOLOGY</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d8b10934-897e-4baa-8d2d-f89c48f4a26b"></a><a name="section-9.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></h2>
<p class="First">The usual initial dosage of timolol maleate is 10 mg twice a day. During maintenance therapy the 20 mg daily dosage may be administered as a single dose. Total daily dosage may be increased to a maximum of 30 mg, given in divided doses, or decreased to 10 mg once per day, depending on clinical response and tolerability. If a satisfactory response is not obtained after 6 to 8 weeks use of the maximum daily dosage, therapy with timolol should be discontinued.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_f19266b9-fe05-4685-9395-fa6e0d43b281"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Timolol Maleate Tablets, USP are available containing 5 mg, 10 mg and 20 mg of timolol maleate, USP.</p>
<p>The 5 mg tablets are green, unscored, flat-faced round tablets debossed with <span class="Bold">M </span>over<span class="Bold"> 55</span> on one side of the tablet and blank on the other side. They are available as follows:</p>
<p>NDC 0378-0055-01<br>bottles of 100 tablets</p>
<p>The 10 mg tablets are green, scored, flat-faced round tablets debossed with <span class="Bold">M</span> above the score and <span class="Bold">221</span> below the score on one side of the tablet and blank on the other side. They are available as follows:</p>
<p>NDC 0378-0221-01<br>bottles of 100 tablets</p>
<p>The 20 mg tablets are green, scored, capsule-shaped tablets debossed with <span class="Bold">M</span> to the left of the score and <span class="Bold">715</span> to the right of the score on one side of the tablet and blank on the other side. They are available as follows:</p>
<p>NDC 0378-0715-01<br>bottles of 100 tablets</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p>Mylan Pharmaceuticals Inc.<br>Morgantown, WV 26505</p>
<p>REVISED AUGUST 2006</p>
<p>TIM:R15</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_2eba6e0a-e042-4412-858f-9eb5dcb0a81c"></a><a name="section-11"></a><p></p>
<h1> </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 5 mg</span></p>
<p><span class="Bold">NDC 0378-0055-01</span></p>
<p><span class="Bold">Timolol</span><br><span class="Bold">Maleate</span><br><span class="Bold">Tablets, USP</span><br><span class="Bold">5 mg</span></p>
<p><span class="Bold">Rx only      100 Tablets</span></p>
<p>Each tablet contains:<br>Timolol maleate, USP          5 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p><span class="Bold">Usual Adult Dosage: </span>See accom-<br>panying prescribing information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RM0055A10</span></p>
<div class="Figure">
<a name="id1274"></a><img alt="Timolol Maleate Tablets, USP 5 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57c62928-63d8-4505-9b9e-c085a3a12c95&amp;name=7f38508a-5a77-4fe1-b1bc-fb26470b02bb-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_a18e4068-519b-447e-b3f3-5aa4291a8c42"></a><a name="section-12"></a><p></p>
<h1> </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 10 mg</span></p>
<p><span class="Bold">NDC 0378-0221-01</span></p>
<p><span class="Bold">Timolol</span><br><span class="Bold">Maleate</span><br><span class="Bold">Tablets, USP</span><br><span class="Bold">10 mg</span></p>
<p><span class="Bold">Rx only      100 Tablets</span></p>
<p>Each tablet contains:<br>Timolol maleate, USP           10 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p><span class="Bold">Usual Adult Dosage: </span>See accom-<br>panying prescribing information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RM0221A10</span></p>
<div class="Figure">
<a name="id1324"></a><img alt="Timolol Maleate Tablets, USP 10 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57c62928-63d8-4505-9b9e-c085a3a12c95&amp;name=7f38508a-5a77-4fe1-b1bc-fb26470b02bb-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_7b3d2547-ca2f-4b0f-9305-d607bf706456"></a><a name="section-13"></a><p></p>
<h1> </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 20 mg</span></p>
<p><span class="Bold">NDC 0378-0715-01</span></p>
<p><span class="Bold">Timolol</span><br><span class="Bold">Maleate</span><br><span class="Bold">Tablets, USP</span><br><span class="Bold">20 mg</span></p>
<p><span class="Bold">Rx only      100 Tablets</span></p>
<p>Each tablet contains:<br>Timolol maleate, USP          20 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p><span class="Bold">Usual Adult Dosage: </span>See accom-<br>panying prescribing information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RM0715A9</span></p>
<div class="Figure">
<a name="id1374"></a><img alt="Timolol Maleate Tablets, USP 20 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57c62928-63d8-4505-9b9e-c085a3a12c95&amp;name=7f38508a-5a77-4fe1-b1bc-fb26470b02bb-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TIMOLOL MALEATE 		
					</strong><br><span class="contentTableReg">timolol maleate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-0055</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TIMOLOL MALEATE</strong> (TIMOLOL ANHYDROUS) </td>
<td class="formItem">TIMOLOL ANHYDROUS</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;55</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-0055-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA072668</td>
<td class="formItem">06/08/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TIMOLOL MALEATE 		
					</strong><br><span class="contentTableReg">timolol maleate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-0221</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TIMOLOL MALEATE</strong> (TIMOLOL ANHYDROUS) </td>
<td class="formItem">TIMOLOL ANHYDROUS</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;221</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-0221-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA072668</td>
<td class="formItem">06/08/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TIMOLOL MALEATE 		
					</strong><br><span class="contentTableReg">timolol maleate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-0715</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TIMOLOL MALEATE</strong> (TIMOLOL ANHYDROUS) </td>
<td class="formItem">TIMOLOL ANHYDROUS</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;715</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-0715-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA072668</td>
<td class="formItem">06/08/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Pharmaceuticals Inc.
							(059295980)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cb884a5e-bc13-43d8-9b2f-f3ee50db896c</div>
<div>Set id: 57c62928-63d8-4505-9b9e-c085a3a12c95</div>
<div>Version: 5</div>
<div>Effective Time: 20060817</div>
</div>
</div> <div class="DistributorName">Mylan Pharmaceuticals Inc.</div></p>
</body></html>
